Logo Image
Viewing
Opinion|Videos|January 31, 2025

Faricimab Molecular Design and Role of Ang-2

Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases.

Episodes in this series

Video content above is prompted by the following:

  • What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases?

Related Content

Latest CME

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity
Video

Precision Vision: Integrating Mechanistic Insight and Clinical Strategy in ADC-Associated Ocular Toxicity

Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH

View more
Treatment Optimization in the Evolving Anti-VEGF Era
Video

Treatment Optimization in the Evolving Anti-VEGF Era

Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS

View more
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis
Video

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

View more
(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights
Video

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

View more
(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management
Video

(CME Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

Rahul Tonk, MD; Jade Coats, OD, FAAO; Aaleya Koreishi, MD; Zeba Syed, MD

View more